In the phase II Mineralocorticoid Receptor Antagonist Tolerability Study (ARTS) trial, the authors demonstrated a similar efficacy of the daily finerenone treatment (5 or 10 mg) compared to spironolactone in patients suffering from HF with a reduced ejection fraction and mild CKD and with lower increases in the serum potassium levels and slight reduction in the eGFR [66]. This evidence concerns the gene NR3C2 and hydrops fetalis.